AveXis and Its Potential ALS Gene Therapy to Be Purchased by Novartis for $8.7B April 9, 2018 AveXis and Its Potential ALS Gene Therapy to Be Purchased by Novartis for $8.7BSource: ALS News TodayPublished on 2018-04-09By Grace Frank
